Navigation Links
Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
Date:2/11/2009

EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma.

LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets the bone, specifically bone cancer, and is used to treat pain caused by cancer that has metastasized or spread to the bone. Velcade (bortezomib) is approved for the treatment of multiple myeloma alone and in addition to chemotherapy. Preclinical studies have reported that the combination of Velcade with Quadramet is much more effective than either drug alone in its anti-myeloma effects.

Published in the journal Clinical Cancer Research, this US-based Phase 1 study included 39 multiple myeloma patients at three clinical oncology sites. Noted oncologist and myeloma specialist, Dr. James R. Berenson was Principal Investigator.

The Phase 1 study evaluated the combination of radiotherapy, a drug that targets bone and bone marrow, with Velcade in order to determine efficacy and safety among patients who had been previously treated. This groundbreaking study marks the first attempt to evaluate targeted radiotherapy with the potent myeloma drug Velcade for myeloma patients.

Dr. Berenson reports, "By using less Velcade than in previous studies along with Quadramet, responses were observed even among patients who were failing Velcadebased therapy. Some patients achieved complete responses with this novel combination treatment in this Phase 1 study. Patients were given 4 doses of Velcade every 8 weeks instead of the standard 4 doses every 3 weeks, and we observed much less peripheral neuropathy with this less intensive schedule. Overall this was a very well tolerated treatment for the patients."

James R. Berenson, MD is a 25 year veteran in the field of oncology wi
'/>"/>

SOURCE Oncotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
(Date:3/27/2015)... , March 27, 2015 Concord ... "Company") (NYSE: CCM ), a leading specialty ... largest network of radiotherapy and diagnostic imaging centers ... the signing of a purchase agreement under which ... owned subsidiary of the Company, agreed to acquire ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... BMN 701, a novel fusion protein of insulin-like growth factor ... treatment of Pompe disease. "We have a strong ... medical needs and expect to leverage our clinical and regulatory ...
... Mass., Jan. 19, 2011 Boston Scientific Corporation (NYSE: ... a definitive merger agreement, under which the Company will ... Plymouth, Minnesota.  Atritech has developed a novel device designed ... atrial fibrillation who are at risk for ischemic stroke. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 2BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 3Boston Scientific to Acquire Atritech 2Boston Scientific to Acquire Atritech 3Boston Scientific to Acquire Atritech 4Boston Scientific to Acquire Atritech 5Boston Scientific to Acquire Atritech 6
(Date:3/27/2015)... 2015 On February 21, 2015, ... the Stardust Penthouse on the rooftop of the ... leading sustainable product TV and film placement producer, ... event, which featured some of the world’s top ... and services. , “We were honored to have ...
(Date:3/27/2015)... Jose, CA (PRWEB) March 27, 2015 While ... week’s 2015 GPU technology conference (GTC) , the CEO ... fight cancer and push the human lifespan well beyond the ... MD informatics company , is one of 12 companies ... , While other startups in the GTC Emerging Companies ...
(Date:3/27/2015)... March 27, 2015 DrugDev announced company ... Easy was named to the 2015 Philadelphia Business Journal ... list spotlights 40 dynamic, up-and-coming leaders less than 40 ... involvement. Winners are honored at an awards program in ... Philadelphia Business Journal. , Lyn Kremer, Publisher of the ...
(Date:3/27/2015)... 2015 The report “CountryFocus: Healthcare, Regulatory ... of information on and analysis of the healthcare, regulatory ... the US in 2013 amounted to 316.1 million, having ... 0.8% from 2008. The country’s increasingly elderly population and ... help to boost the growth of the pharmaceutical market, ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 SMI ... today announced it has launched the SM1120 MEMS based ... market. The microsensor profile at only 220um x ... maneuverability to reach challenging locations. With industry leading ... hour, the SM1120 provides a broad operating pressure range ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2
... examination is its limited capacity to determine the ... between benign and malignant lymph nodes and focal ... difficult and frequently requires EUS-guided fine needle aspiration ... been presented as a novel technique that can ...
... Calgary, AB- The most disabling aspect of Tourette syndrome ... conjunction with another disorder. The most frequent co-occurring ... disorder (ADHD), though the cause of this association is ... but having two means coping with more than twice ...
... risky behaviors, study finds , , WEDNESDAY, April 15 (HealthDay News) ... children are more likely to slip into trouble, from getting ... study has found. , But adolescents whose mothers reported that ... fare better. , "Adolescents are in that difficult time of ...
... Hard Post-Spring BreakLYNBROOK, N.Y., April 15 ... other technicians at Arrow Exterminating are finding bed bugs ... keyboards, between the pages of books, inside electric switches, ... cell phone. "We,ve never seen anything like this," ...
... Based on its recent analysis of the ... (CT) markets market, Frost & Sullivan recognizes Zecotek ... & Sullivan Award for Enabling Technology. Zecotek,s outstanding ... solid-state photo detector technologies that will help deliver ...
... EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) ... Dividend by 11 Percent - , , ABBOTT ... today announced financial results for the first quarter ended March 31, ... Diluted earnings per share, excluding specified items, were $0.73, reflecting ...
Cached Medicine News:Health News:Can EUS elastography help distinguish benign from malignant tissue? 2Health News:Tourette syndrome misconceptions only one battle for patients 2Health News:Deployment Takes Toll on Military Moms and Teens 2Health News:Deployment Takes Toll on Military Moms and Teens 3Health News:Bed Bug Infestation an Epidemic; Bugs Found in Cell Phone, TVs and Keyboards 2Health News:Bed Bug Infestation an Epidemic; Bugs Found in Cell Phone, TVs and Keyboards 3Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 3Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 4Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 2Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 3Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 4Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 5Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 6Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 7Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 8Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 9Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 10Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 11Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 12Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 13Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 14Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 15Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 16Health News:Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 17
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: